• DUSS · OTC
  • EMXC · OTC
  • TYTN · OTC
  • TDGI · OTC
  • Industry News

    Industrial Nanotech, Inc. Announces More Textile Mills Using Company’s Patented Nansulate® Insulation Technology

    Posted on July 5, 2011 by Dana Salvo

    INTKNAPLES, Fla.-Industrial Nanotech, Inc. (Pink Sheets:INTK.pk), an emerging global leader in nanoscience energy saving solutions, announced today that additional textile mills are incorporating the Company’s patented line of energy saving protective coatings into their sustainability initiatives worldwide.

    “We are currently doing a pilot project with Hanesbrands, Inc. In the event that Nansulate® performs as well for their textile equipment as it has on the textile equipment of multiple companies at multiple factories around the world for the past half decade, they will begin applying Nansulate to their heat process equipment at their factories,” states Stuart Burchill, CEO/CTO of Industrial Nanotech, Inc. “Considering that Coats, PLC, the world market leader in industrial yarns and threads and consumer crafts, stated publicly that the use of Nansulate® on heat process equipment in 37 of their factories in 27 countries will reduce their steam consumption by 10 percent and their global carbon footprint by 2%, we are optimistic that we will be able to provide the same benefits to Hanesbrands, Inc. and that this will result in a significant value added proposition for both their company and Industrial Nanotech, Inc.”

    Hanesbrands, Inc. is based in Winston-Salem, NC. The company’s apparel brands include: Hanes®, Champion®, Playtex®, Bali®, L’eggs®, Just My Size®, Barely There® and Wonderbra®.

    Nansulate® coatings have been used by numerous textile manufacturers for insulation of their dyeing machines, steam pipes, heat exchangers and other equipment. Henateks Textile, a manufacturer for Nike, Adidas, and others, documented a 20% reduction in liquid natural gas consumption which was attributed directly to Nansulate® High Heat insulation coating being used to insulate their steam process system. This resulted in a 2007 and 2008 cost savings of $852,437.00 US and a payback period of only 7 months. Erenko Textile, a manufacturer for Walt Disney and other brands, performed side-by-side trials on same capacity machines running a 60 minute cycle of 60 degrees C. The machine coated with Nansulate® insulation, reduced steam supply cycles from 24 injections over the 60 minutes down to 2 injections, reducing energy consumption by a minimum of 20% and providing an overall 10% reduction in unit material production costs. The coatings have been featured in multiple textile specific magazines and publications for their energy saving performance in the textile industry.

    About Nansulate®

    Nansulate® is the Company’s patented product line of award winning, specialty coatings containing a nanotechnology based material and which are well-documented to provide the combined performance qualities of thermal insulation, corrosion prevention, resistance to mold growth, fire resistance, chemical resistance and lead encapsulation in an environmentally safe, water-based, coating formulation. The Nansulate® Product Line includes industrial, residential, agricultural and solar thermal insulation coatings. Additional information about the Company and its products can be found at their websites, (www.industrial-nanotech.com) and (www.nansulate.com). Blog: www.nansulate.com/nanoblog, Twitter: www.twitter.com/NanoPioneer, Facebook: www.facebook.com/Nansulate.

    About Industrial Nanotech Inc.

    Industrial Nanotech Inc. is a global nanoscience solutions and research leader and member of the U.S. Greenbuilding Council and an official ALLY organization with the U.S. Dept. of Energy “Save Energy Now” program. The Company develops and commercializes new and innovative applications for sustainable nanotechnology which are sold worldwide.

    Blue Gold Beverages, Inc. Acquires USA Based Epic Nutrition, Inc.

    Posted on June 16, 2011 by Dana Salvo

    BGBVBlue Gold Beverages, Inc. (PINK SHEETS:BGBV) is pleased to announce it has signed a definitive agreement to acquire 100% of the shares of Epic Nutrition, Inc. a manufacturer and distributor of their own proprietary brands Quick NRG Energy Shot™, Goodnight™ (Sleep & Relaxation Supplement), NRG Pro-N-Go™ (Protein Energy Shot) and COLDsense™ natural cold and flu remedy.

    “The addition of Epic Nutrition, Inc. as a wholly owned subsidiary of Blue Gold Beverages, Inc. provides us with a solid marketing platform from which to grow our specialty beverage business in North America” comments Mr. Larry Latowsky, the recently appointed Chairman of the Board of Blue Gold Beverages, Inc. “Epic Nutrition, Inc. is a company I know very well and has developed several new proprietary products that we intend to also market through the Canadian distribution channels already acquired by Blue Gold Beverages from Epic Canada.

    With the introduction of these new products, and through a new sales agreement with major US broker, combined with our new distribution agreement for PitBull Energy Bars we anticipate revenues to reach in excess of $20 million dollars by the end of 2012.”

    “Epic Nutrition and its related products are companies that are poised for dramatic growth with outstanding management” says Mr. Daniel Solomita, President and CEO of Blue Gold Beverages, Inc. The NRG brand has been very well received by retailers and the newly developed Goodnight, a sleep & relaxation supplement, COLDsense™ natural cold and flu remedy and NRG Pro-N-Go protein infused energy shot will be the foundation of our future success. These new products will be marketed in 2011 in the United States by one of the leading distributors in this category”.

    Mr. Solomita further states “The acquisition of Epic Nutrition Inc. and the beverage sales division of Epic Canada provides a platform for growth in the specialty beverage sector and we expect to dramatically increase sales as a result of the introduction of our new products as well as the finalization of an exclusive distribution agreement with one of the country’s foremost retail distribution companies”.

    ABOUT THE ENERGY DRINK INDUSTRY: Energy drinks refer to beverages that contain, besides calories, caffeine in combination with other presumed energy-enhancing ingredients such as taurine, herbal extracts, and B vitamins. Energy drinks fall into the category of functional and include ready-to-drink (RTD), shots, and in powder form. Globally, energy drinks hold 47.3% of the functional beverage’s overall market share, while in the United States they comprise 62.6% (Datamonitor 2008a, 2008b). Energy drinks in particular have experienced impressive growth of more than 240% in the United States, as well as abroad, from 2004 to 2009 (Mintel 2009. The U.S. energy drink industry is anticipated to more than double and reaches an astounding $19.7 billion in 2013, which is almost a 160% increase from 2008 . Within the functional beverage category, the energy drink segment has experienced the largest volume growth and increased annual sales, both in the United States and abroad, reaching $4.8 billion in 2008 in the United States alone (Datamonitor 2008a). Read the rest of this entry »

    Nutra Pharma Announces Exclusive Distributor for Their Nyloxin Pain Relievers in Lebanon

    Posted on June 4, 2011 by Dana Salvo

    NPHC(06/03/11) - Nutra Pharma Corp. (OTC.BB:NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain announced today that it has selected Alampharm to serve as the exclusive distributor in Lebanon for its Nyloxin™-branded pain relievers.

    “We are excited to be working with Alampharm to introduce our Nyloxin products into Lebanon,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As the leading pharmaceutical distributor in Lebanon, Alampharm is the perfect partner to introduce and distribute our products into the Middle East,” he added.

    Alampharm is a leading pharmaceutical company operating in Lebanon and highly recognized in the Middle East. Alampharm maintains the highest quality customer service by ensuring the safety of the product; they are focused and dedicated towards their customers, who in turn benefit from emerging new healthcare products such as Nyloxin™. Alampharm is continuously introducing Brand Name and Generic Pharmaceuticals that are FDA-approved Vaccines, Injectables, Over-the-counter Drugs, Nutritional Supplements, Health and Beauty Products, and Home Healthcare products into the Lebanese market. Alampharm, located in Beirut, also has medical representatives all over the country in addition to Syria and has been widely serving the pharmaceutical needs of medical institutes, hospitals, clinics, specialized medical facilities, pharmacies, as well as distributing domestically and regionally with great success since 2004.

    “We are so enthusiastic about continuing the registration of Nyloxin and introducing it to the market,” commented Dr. Khaled Alam, the Chief Executive Officer of Alampharm. “Nyloxin will be promoted through professional medical representatives to Orthopedics, Neurologists, and Oncologists and we will position Nyloxin as the first choice treatment of chronic pain management,” he continued. “In other words, the concept of analgesics in Lebanon and Syria will be changed and Nyloxin will constitute a revolution in the concept of pain treatment. The Arab Community is now ready to bring a positive change in their life, and put an end to their highly rated chronic aches. This will be procured by Nyloxin,” he concluded.

    According to the World Health Organization (WHO), there are 8700 doctors, 3562 pharmacists, and around 4000 nurses in Lebanon. The characteristics of the medical practice in Lebanon include freedom to prescribe medicines, patient’s freedom to choose the doctor and direct agreement concerning fees. The physician therefore have the latitude to market any specific brand to their patient population. Read the rest of this entry »

    TBIO.OB -Transgenomic Inc. - $1.25

    Posted on May 19, 2011 by Dana Salvo


    Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Product offerings include the WAVE Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,500 systems have been installed in customers’ labs in more than 50 countries. The SURVEYOR Mutation Detection Kits provide reagents and protocols for high sensitivity detection of mutations in DNA. HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic karyotyping and FISH analyses. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials. The Transgenomic Molecular Laboratories specialize in molecular diagnostics for cardiology, neurology, mitochondrial disorders, oncology, hematology, molecular pathology and other inherited diseases. Transgenomic believes there is a significant opportunity to continue growing the demand for its molecular-based testing by leveraging core technologies, experience, and expertise in biomarker analysis. In addition, the company continues to seek out and evaluate new technologies and new tests to extend its offerings in molecular diagnostics and pharmacogenomics services.

    WNDM Files Q1 Results; Company Reports Record Revenue; Cash Position at All-Time High

    Posted on May 18, 2011 by Dana Salvo


    May 18, 2011 — Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions, announced financial results for its first quarter of 2011. For the three-month period ending March 31, 2011, revenue was $935,412, a 1,303% increase over first quarter 2010 net revenue of $66,960. The increase in revenue was primarily attributable to enhanced sales efforts in 2010, which continued into the first quarter of 2011. The Company had a loss of $2,743,921 for the first quarter of 2011, as compared to a loss of $1,244,507 for the first quarter of 2010. The loss in the first quarter of 2011 included a non-cash loss of $1,950,882 related to the conversion of certain debt of the Company into equity. Cash flow from operations at 3/31/11 was positive for the first time in the Company’s history, $124,278 as compared to a negative cash flow from operations of $284,810 at 3/31/10.

    Key Financial Comparisons between Q1 2011 & Q1 2010:

    Gross profit rose 1717% to $840,994 versus $46,293.
    Current assets rose 169% to $2,288,521 versus $850,092.
    Current liabilities dropped 29% to $2,468,869 versus $3,479,189.
    Weighted-average number of common shares rose 37% to 46,423,395 from 33,948,681
    Stockholders’ equity rose 87% to $5,377,356.
    Cash on hand as of March 31, 2011, was $1,021,507 versus cash of $50,835 in the prior comparable period.

    Scott Haire, Wound Management Technologies CEO, commented, ” We are very pleased with our first quarter results as well as with the Company’s outlook. During the first quarter, Wound Management achieved several key milestones: a record high in quarterly revenues equal to roughly all of the Company’s 2010 revenues, a significantly improved balance sheet, our first positive cash flow from operations, and the completion of financing that left the company with more than $1M in cash.”

    “The Company is executing extremely well. We expect revenues to continue to increase throughout the remainder of 2011 driven primarily by sales from our existing distributors as well as the opening of new markets for CellerateRx® worldwide.”

    Deborah Jenkins Hutchinson, President of Wound Management Technologies, stated, “We have met the initial goals of our 2011 business plan. The Company has reached milestone revenue targets, rolled out direct-to-consumer sales, and closed an agreement with a major channel partner in Juventus. In Q2, the Company should continue to execute on the business initiatives stated in the Letter to the Shareholders dated April 20, 2011. Some of the progress investors can anticipate includes increasing sales, an agreement for CellerateRx® to go on formulary at a major healthcare system, and entry into the government healthcare market.”

    Imperial Provides Update on Oil Sands Project

    Posted on May 16, 2011 by Dana Salvo

    Imperial Petroleum

    EVANSVILLE, Ind. Imperial Petroleum, Inc. (OTCQB: IPMN) announced that its wholly-owned subsidiary, Arrakis Oil Recovery, LLC, has successfully completed commercial scale demonstration tests for multiple parties on oil sands from various locations. The Company has entered into Letters of Intent with at least two of the parties so far to begin the development of oil sand recovery operations later this summer and is completing definitive agreements to begin each project.

    “The commercial scale demonstrations we conducted were successful in recovering the native oil from the oil sands processed which had been delivered from several areas throughout the United States. We believe that the Arrakis technology is the most advanced, cost-effective and eco-friendly processing technology available for recovering bitumen from tar and oil sands,” Jeffrey T. Wilson, President of Imperial said. “ On the heels of the President’s newly announced energy policy, we believe that the Arrakis process will begin to unlock the potential of some 20 billion barrels of recoverable oil sands located in the United States. Upon completion of definitive agreements later this month with each of the parties, we will deploy the commercial unit located in Houston to the field while we build a second and possibly a third unit for separate project sites. We expect to be operational with the first unit later this summer. Since our process has no air, water or hydrocarbon emissions issues and uses a non-toxic, biodegradable chemical under low dosage rates in a recycled operation, we do not expect to encounter any significant permitting issues at any of the proposed sites.”

    Imperial is an energy company headquartered in Evansville, Indiana.

    This press release may contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described herein. Although the Company believes that the expectations in such statements are reasonable, there can be no assurance that such expectations will prove to be correct.

    Tytan Holdings, Inc. CEO Heads to China to Inspect New Products

    Posted on May 14, 2011 by Dana Salvo


    KALAMA, Wash., May 11, 2011 — Tytan Holdings, Inc. (TYTN.OTC), is pleased to announce that CEO Mark Leonard will be leaving for China on May 12th to inspect the brand new tractors and implements ready to be shipped to the U.S.  CEO Mark Leonard will be leaving for China on May 12, 2011 to conduct the inspection.  ”We want to be absolutely sure that every item we ordered meets the expectations of our waiting customers,” stated Leonard. These new products will expand Tytan’s offerings and its ability to enter new markets.  This new shipment is expected to arrive just before the start of the 3rd quarter and will include the New 304 Mini 4WD Tractor + Front Loader.  The All New Mini Tractor offers affordable pricing, a high powered constitution and a wide variety of capabilities that others just do not have.  ”It is just great for cleaning stalls, grooming small acreages and will be easily transportable.”

    “We expect the New Mini to have wide dealer acceptance,” said Leonard. “Dealers we have never met have been calling looking for exactly this kind of tractor.”  Based on the volume of calls, the Company expects the demand for the low cost, fuel efficient, and durable 304 Mini + Front Loader to be very high.  The 2nd and 3rd quarters of this year will be the introduction period.  By the 4th quarter, the Company believes that customers reporting the reliability and ruggedness of these remarkable machines will generate significant momentum in sales.  ”Word of mouth is the best advertising you can get,” said Leonard, adding, “We are eager to put our goods in the dealers’ hands as soon as possible.”

    In other news, the Company is pleased to announce the construction of a new corporate website currently viewable at http://www.lowcg.com/cm/Home.html . Once pictures of the new products are added to the site, it will be linked to www.tytantractor.com and www.titantractor.com.  Retail customers will be directed to www.tractorboss.com and its companion site www.tractorhp.com for on-line sales, parts catalogues and customer service.  Looking ahead, the Company acquired www.BuiltinUnitedStates.com domain address which will be used when the Company begins manufacturing certain goods in the USA.

    The Quarterly Report for the first quarter of 2011 will be released on time with OTCmarkets.com.  Mr. Leonard reports that sales for this quarter were sluggish due to poor weather, a weak economy and the Company’s intense focus on exciting future projects.  The arrival of the new products from China, sometime in the second quarter, bodes well for an uptrend in sales.  ”We couldn’t be happier about the quality of the new designs coming from China,” stated Leonard, adding, “I think our customers are going to love this stuff.  It’s exactly what they’ve been asking us for.”

    Read the rest of this entry »

    Industrial Nanotech, Inc. Enters Qatar Market - Sees Great Opportunities in Country With 14% of the World Total Natural Gas Reserves, Highest GDP Per Capita, and 15 Billion Barrels Proven Oil Reserves

    Posted on April 27, 2011 by Dana Salvo


    NAPLES, Fla.- Industrial Nanotech, Inc. (Pink Sheets:INTK.pk), an emerging global leader in nanotechnology based energy saving solutions, today announced that the Company has entered into an agreement with Qatar Nanotechnology Company to serve as exclusive distributor in Qatar for Industrial Nanotech, Inc.’s patented Nansulate® product line of thermal insulation and protective coatings. Qatar Nanotechnology is a distributor and service provider of nanotechnology based solutions to commercial, industrial, and residential customers in Qatar and the Gulf Region. Their management team owns numerous companies in the region and has a long-term track record of success.

    “We look forward to expanding into this country with Qatar Nanotechnology Company,” stated Francesca Crolley, V.P. Business Development for Industrial Nanotech, Inc. “Their management team has an excellent record of commercializing new technologies. Their Technical Director has worked for major U.S. companies including Nova Measuring Instruments, Philip Morris USA and Intel. Their President and CEO has 19 successful businesses ranging from cleaning services to construction services, which they plan to supply with Nansulate® coating solutions. Qatar is a fast growing area, which is investing heavily into new housing and office buildings, as well as in new infrastructure and equipment and plants for the oil, gas, refining and petrochemicals sectors. We look forward to this being an important market for Industrial Nanotech.”

    Qatar has proved oil reserves of 15 billion barrels, which should enable continued output at current levels for 37 years. Qatar’s proved reserves of natural gas exceed 25 trillion cubic meters, about 14% of the world total and third largest in the world. In 2010, Qatar had the world’s highest GDP per capita, while the economy grew by 19.40%, the fastest in the world. The main drivers for this rapid growth are attributed to ongoing increases in production and exports of LNG, oil, petrochemicals and related industries. In 2009, Qatar was the United States’ 5th largest export market in the Middle East, trailing behind the U.A.E., Israel, Saudi Arabia and Egypt. Qatar has attracted an estimated $100 billion in investment, with approximately $60-70 billion coming from the U.S. in the energy sector. It is estimated that Qatar will invest over $120 billion in the energy sector in the next ten years. Read the rest of this entry »

    WNDM Signs $1.5 Million Multiyear Regional Distribution Agreement

    Posted on April 12, 2011 by Dana Salvo


    April 12, 2011 - Wound Management Technologies, Inc., (OTCQB: WNDM) a leader in advanced wound care solutions, today announced that the Company has signed a multi-year agreement with Omni Medical Products of McAllen, Texas to distribute CellerateRX® gel products in select states in the southwestern U.S.  To maintain the distributorship, the agreement calls for 1st year sales of at least $650,000 and additional sales each subsequent year.

    According to Deborah Jenkins Hutchinson, President of Wound Management Technologies, “We are pleased to have Omni Medical Products distributing Wound Management’s gel products in select states.  This agreement is part of our broader campaign to establish CellerateRX® as the standard of care in wound treatment.”

    Ron Mathis, Senior VP of Sales stated, “I am optimistic that as our sales increase we will continue to find broad distribution channels for the product. This new relationship along with our recent television campaigns should help to provide the exposure necessary to grow the company.”

    Scott Haire, WNDM CEO was quoted, “It is exciting to watch as our revenues continue to grow, partnerships like this with Omni along with the recent announcement of our Middle East orders are all very encouraging signs that we will achieve meeting our 2011 revenue projections.”

    For additional news and information concerning the CellerateRX® line of wound care products, please visit Wound Management Technology’s newly re-launched product website www.CellerateRX.com.

    About Wound Management Technologies, Inc.

    Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage.  More information can be found on the company’s web sites: http://www.wmgtech.com and http://www.celleraterx.com.

    WNDM Secures Additional International Sales; $150 K in New Orders for 2011

    Posted on April 7, 2011 by Dana Salvo

    WNDMFORT WORTH, Texas, April 7, 2011 — Wound Management Technologies, Inc., (OTCBB:WNDM) a leader in advanced wound care solutions, today announced that its Pharma Tech International Joint Venture, which sells wound care products within key international markets, has received new orders for the Company’s line of CellerateRX® powder and gel products.  In Lebanon, the subsidiary just completed a $50,000 order for powder and gel with a second $100,000 order scheduled for shipment later this Month with expectations to ramp up to larger orders by 3rd quarter.

    According to Deborah Jenkins Hutchinson, President of Wound Management Technologies, “I am very excited by these orders and the prospect for further growth in overseas sales.  We believe that the international market represents a significant opportunity for our products due, in part, to the region’s high rate of diabetes and its associated complications.”

    For additional news and information concerning the CellerateRx® line of wound care products, please visit Wound Management Technology’s newly relaunched product website www.CellerateRX.com.

    About Wound Management Technologies, Inc.

    Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage.  More information can be found on the company’s web sites: http://www.wmgtech.com and http://www.celleraterx.com.